OBJECTIVES: To assess dosing differences between duloxetine and pregabalin initiators among elderly patients with fibromyalgia. METHODS: Using a large US administrative claims database, we examined fibromyalgia patients aged 65 and above with Medicare supplemental insurance who initiated duloxetine or pregabalin in 2006. Initiation was defined as no duloxetine or pregablin pill coverage in the previous 90 days, with the index date defined as the first initiation date. The duloxetine or pregabalin cohorts were constructed based on the index agent. All individuals selected had continuous enrollment in the 12 months pre-and post-index periods and at least 31 duloxetine or pregabalin supply days in the 12 months post-index period. Duloxetine initiators with diabetic peripheral neuropathic pain (DPNP) or depression, and pregabalin initiators with DPNP, post-herpetic neuralgia or epilepsy diagnosis in the 12-month pre-index period were excluded. Average initial daily dose, annual average daily dose, average daily dose of the first 12 prescriptions of duloxetine or pregabalin, and percent of daily dose change from previous prescription were compared between cohorts. RESULTS: Patients in the duloxetine (n = 624) or pregabalin (n = 1,199) cohorts had a mean age of 74 years. The average initial daily dose was 51.34 mg for duloxetine and 145.71 mg for pregabalin, respectively. Duloxetine patients had an annual average daily dose of 50.81 mg, while 162.82 mg for pregabalin patients. The average daily dose for the first through twelfth duloxetine prescriptions ranged 49.49-53.96 mg, while the range for pregabalin was between 145.71 mg and 216.96 mg. The percentages of changes in daily dose from previous prescriptions were −4.5-2.8% for duloxetine and 0.6-12.4% for pregabalin, respectively. CONCLUSIONS: Duloxetine and pregabalin had very different dosing profiles among elderly patients with fibromyalgia. Specifically, duloxetine initiators had relatively stable average daily dose over time, while pregabalin initiators had clear dose escalation over the 12-month follow-up period. OBJECTIVES: Obesity (defined as body mass index (BMI) > 30) is a major contributor to increased morbidity, mortality, and health care expenditures. We used data from the Medical Expenditure Panel Survey (MEPS) to construct a lifetime cost and outcomes model explicitly accounting for morbid obesity. Then, we estimated the potential economic value of weight reduction in terms of cost savings plus the value of improvements in life expectancy and quality of life. METHODS: We constructed a Markov model with a lifetime horizon using death and BMI health states: 18. 5-24.9, 25-29.9, 30-34.9, 35-35.9, 40-44.9, 45-49.9, 50 < . MEPS Panels 6-10 (2001-2006 provide 91,000 observations to estimate transition probabilities. We estimated discounted (3% per annum) lifetime costs and quality-adjusted life years (QALYs) using regressions with gender, age, and BMI as predictors. Utilities were mapped from SF-12 to EQ-5D. RESULTS: In the base case, for a 45 year-old female with BMI 45-49.9, a 10%, 20%, and 30% BMI reduction is associated with discounted lifetime economic value gain of $20,000, $35,000, and $51,000, respectively. Transition probability estimates show that patients tend to stay in the same BMI category from year to year. Average annual cost increases significantly (p < 0.01) with BMI (+$362 per 5 BMI unit increase), age (+$118 for each year of age) and gender (+$547 for females). For utility levels, BMI (−0.0246 per 5 BMI unit increase), age (−0.0036 for each year of age), and gender (−0.0355 for females) were all significant (p < 0.01). CONCLU-SIONS: MEPS panels provide repeated measures of BMI allowing a projection of the natural history of obesity from a single data source. Obesity is a significant driver of costs and QALYs: we show that a reduction in BMI of obese patients could be associated with lower costs and better quality-adjusted life expectancy. MEPS provides only self-reported BMI data, and this potential bias deserves further exploration.
events and long-term complications. Mean age-adjusted quality of life of a healthy patient was estimated using life tables. Costs and quality-adjusted life years (QALYs) were discounted at 5%. Base-case values were determined using Monte Carlo simulation and sensitivity analyses were conducted. Net benefit of each strategy was analyzed at different willingness-to-pay (WTP) thresholds ($0 to $150,000) to determine the most cost-effective strategy. RESULTS: In the base-case, ELISA resulted in lifetime costs and utilities of $9028 and 10.5413 QALYs compared with $8849 and 10.5428 QALYs for ELISA/SRA. ELISA was dominated by ELISA/SRA. ELISA/SRA was the most cost-effective strategy for WTP thresholds between $25,000 and $150,000; ELISA was optimal for WTP thresholds under $25,000. ELISA/SRA remained costeffective when thrombosis and bleeding complication costs and probabilities were varied. ELISA was the most cost-effective strategy when specificity was greater than 92.7%. The results were consistent for both prophylactic and treatment doses of unfractionated heparin. CONCLUSIONS: For the base-case scenario, ELISA/SRA is the optimal testing strategy. Health care providers need to take into account the turnaround time for ELISA and SRA results for generalizing the study findings.
PSY23 A COST-EFFECTIVENESS ANALYSIS OF CONVENTIONAL TREATMENT VERSUS BARIATRIC SURGERY FOR OBESE PATIENTS WITH TYPE-2 DIABETES AND HYPERTENSION AS COMORBIDITIES. PRELIMINARY RESULTS UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
Nasciben V, Saggia MG Johnson & Johnson, Sao Paulo-SP, Brazil OBJECTIVES: To assess the cost-effectiveness of the open (OPBARS) and the laparoscopic surgery Roux-en-Y gastric bypass (LAPBARS) versus the conventional nonsurgical treatment (CONVT) for obese patients, in 5 years of follow up, under the Brazilian private payer perspective. METHODS: An analytic decision-tree model was built to estimate costs and outcomes among OPBARS and LAPBARS versus CONVT, measuring weight loss, co morbidities resolution (T-2 diabetes and hypertension; Buchwald 2009) and the impact of that on QALYs for obese patients with BMI > 35. In order to evaluate the differences of surgery against CONV treatment we assumed the same efficacy for OPBARS and LAPBARS. The Brazilian guideline for Health Technology Assessment (Vianna, 2007) was the driver for the study development. A panel of specialists was conducted to obtain local practice from pre-operatory evaluation to the last medical visit 5 years after the procedure. A micro costing technique based on public price lists (SIMPRO 2009, CBHPM 5o Ed) was applied to value the resources usage. Only direct medical costs were considered. A discount rate of 5% was assumed for costs and outcomes. One-way sensitivity analysis was performed to check the robustness of the results. RESULTS: The more sustainable resolution of the co morbidities for OPBARS and LAPBARS resulted in an increase of 1.34 QALYs in 5 years versus CONVT (3.26 QALYs vs. 1.92 QALYs). The total costs for the 5 years were R$ 26, 456 for OPBARS, R$ 32,515 for LAPBARS and R$ 19,217 for CONVT. So, the incremental cost-effectiveness ratio was R$ 7,449 per QALY for OPBARS and R$ 10,395 per QALY for LAPBARS when compared with CONVT. CONCLUSIONS: Findings suggest OPBARS and LAPBARS as safer and cost-effective choices for obesity treatment and co morbidity resolution, under the Brazilian private health care system.
PSY24

COST-EFFECTIVENESS OF HAEMATE P® PROPHYLACTIC TREATMENT FOR BLEEDING EPISODES IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE
Gonzalez-Diaz BE 1 , Contreras I 2 , Martinez-Murillo C 1 , Alvarez J 3 , Fuentes-Mendez F 3 1 Instituto Mexicano del Seguro Social, Mexico, Mexico, 2 Instituto Mexicano del Seguro Social, Delegación Cuauhtémoc. Distrito Federal, Mexico, 3 CSL Behring Biotherapies for life, Mexico, Mexico OBJECTIVES: Patients with sever von Willebrand disease (VWD) are deficient in von Willebrand factor (VWF). These deficiencies can result in painful and sometimes fatal bleeding. The purpose of this study is to develop an economic model for the evaluation of cost-effectiveness ratios between Haemate P® and other plasma-derived FVIII/VWF concentrates treatment in the control or prophylaxis of urgent bleeding of patients with von Willebrand Disease at the Mexican Institute of Social Security (IMSS). METHODS: A cost-effectiveness analysis was developed using a Bayesian decisiontree model. The model simulates costs and effectiveness outcomes in a period of 2O days. The comparators were Haemate P® (loading dose 40-60 kg-1 and maintenance dose 20-40 U kg-1 every 8-24 h) and plasma-derived FVIII/VWF (dose 20 −50 U Kg-1 every 8-24 h). Use of resources and cost data were obtained from expert consensus with hematologist of IMSS. Effectiveness measures were the percentage of avoided bleeding. Effectiveness data and transition probabilities were taken from international published literature. The model was calibrated according to international pharmacoeconomic guidelines. One-way and probabilistic sensitivity analyses were performed using second-order Monte Carlo Simulation approach. RESULTS: The estimates show that patients who receive Haemate P® prevents might bleeding events in 97% while those treated with plasma-derived FVIII/VWF only in the 82%. Mean cost per patient treated with Haemate P® (US$4932) was lower than with plasmaderived FVIII/VWF (US$5,010). Based on ICER's Haemate P® resulted as the dominant therapy. Acceptability curves showed Haemate P® most cost-effective therapy in a range of 80%-90% independently of IMSS willingness to pay. CONCLUSIONS:
The results show that in México, Haemate P® is the most cost-effective in the prophylaxis of bleeding in patients with VWD at IMSS. These results should be taken into account by Mexican decision makers for the management of this disease.
PSY25
COST-EFFECTIVENESS OF NONINVASIVE MAGNETIC RESONANCE DIRECT THROMBUS IMAGING AND ULTRASONOGRAPHY FOR DIAGNOSING DISTAL DEEP VEIN THROMBOSIS
The University of Illinois at Chicago, Chicago, IL, USA, 2 University of the Sciences in Philadelphia, Philadelphia, PA, USA OBJECTIVES: Proper diagnosis of Deep Vein Thrombosis (DVT) at the earliest time is very important so that appropriate therapy can be initiated. Ultrasonography is the most widely used diagnostic technique. Noninvasive magnetic resonance direct thrombus imaging (MRDTI) is a new diagnostic technique that has higher sensitivity and specificity compared to Ultrasonography for distal deep vein thrombosis (DVT). The objective is to identify the most cost-effective strategy for diagnosis of distal deep vein thrombosis. METHODS: A decision-analysis model was constructed using TreeAge Pro software and analyzed using second-order Monte Carlo simulation technique. Diagnostic accuracy was calculated using Bayes' revision method that utilized sensitivity and specificity of the diagnostic tests along with the pretest probability of developing the disease. Outcomes considered were costs, adverse events and quality of life. Quality-adjusted life years were calculated using life expectancy tables. Where applicable, costs in pounds were converted to US dollars and adjusted through use of Consumer Price Index data from Bureau of Labor Statistics. Net benefit of each strategy was analyzed at different willingness to pay (WTP) thresholds ($0 to $150,000) to determine the most cost-effective strategy. RESULTS: Noninvasive MRI is the optimal strategy for diagnosis of distal DVT at all WTP thresholds greater than $25,000. No diagnosis strategy was the most cost-effective strategy when threshold was below $25,000. Sensitivity analysis showed that noninvasive MRI remained costeffective even when all costs were varied by 25%. The model results were affected by the sensitivity of the diagnostic tests. CONCLUSIONS: For base-case scenario, noninvasive MRI is the most cost-effective strategy. Considering the cost-effectiveness and the fact that ultrasonography has higher mortality compared to noninvasive MRI, employing noninvasive MRI appears to the optimal strategy. Health care providers should consider patient population distribution among the risk groups defined by Wells score for generalizing the study results to their setting.
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COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN BRAZIL
Rivas R 1 , Idrovo J 2 , Zapata L 1 1 Guia Mark, Mexico, DF, Mexico, 2 National Institute of Public Health, Cuernavaca, Morelos, Mexico OBJECTIVES: The chronic kidney disease (CKD) is associated with an abnormally elevated level of phosphate in the blood, which contributes to the presence of vascular calcifications, thus increasing the probability of the occurrence of cardiovascular events and death in these patients. The objective of this analysis was to evaluate the incremental cost-effectiveness of the use of sevelamer to manage hyperphosphatemia in Brazil METHODS: A Markov model was created to estimate the monthly costs and benefits of the treatment with sevelamer or calcium tablets in patients with renal failure considering a temporary horizon of 60 months. The transition probabilities were taken from clinical trials identified through a systematic review of literature. The effectiveness measure considered was an increase in patient survival (months). Only direct costs were considered . Costs were calculated using 2009 prices and are expressed in US dollars. In addition, univariate sensitivity analysis and scenario changes were performed. The discount rate was 5%. RESULTS: The expected cost was US$37,477 for calcium and US$58,397 for sevelamer. Patients in calcium group would survive 51 months, compared to the sevelamer group (54 months). The Cost-Effectiveness Ratio with calcium was $734 and with sevelamer was $1073 respectively, and the incremental Cost-Effectiveness Ratio for the implementation of sevelamer vs. calcium was $6135 .(1 USD = 1.8 BRL$) CONCLUSIONS: Sevelamer is a cost-effective drug for the treatment of hyperphosphatemia in patients with CKD in the brazilian context.
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COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN ARGENTINA
Rivas R 1 , Idrovo J 2 , Zapata L 1 1 Guia Mark, Mexico, DF, Mexico, 2 National Institute of Public Health, Cuernavaca, Morelos, Mexico OBJECTIVES: The chronic kidney disease (CKD) is associated with an abnormally elevated level of phosphate in the blood, which contributes to the presence of vascular calcifications, thus increasing the probability of the occurrence of cardiovascular events and death in these patients. The objective of this analysis was to evaluate the incremental cost-effectiveness of the use of sevelamer to manage hyperphosphatemia in Argentina METHODS: A Markov model was created to estimate the monthly costs and benefits of the treatment with sevelamer or calcium tablets in patients with renal failure considering a temporal horizon of 60 months. The transition probabilities were taken from clinical trials identified through a systematic review of literature. The effectiveness measure considered was an increase in patient survival (months). Only direct costs were considered . Costs were calculated using 2009 prices and are expressed in US dollars. In addition, univariate sensitivity analysis and scenario changes were performed. The discount rate was 5%. Exchange rate was 3.6 Argentine pesos (ARS) per 1 US dollar. RESULTS: The expected cost was US$52,558 for calcium and US$69,678 for sevelamer. Patients in calcium group would survive 51 months, compared to the sevelamer group (54 months). The Cost-Effectiveness Ratio with calcium was US$1030 and with sevelamer was US$1280 respectively, and the incremental Cost-Effectiveness Ratio for the implementation of sevelamer vs. calcium was US$5021. ICER of sensitivity analysis doesn't change more than 10% of original scenario. CONCLUSIONS: Sevelamer is a cost-effective drug for the treatment of hyperphosphatemia in patients with CKD in the Argentinian context.
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COST-EFFECTIVENESS ANALYSIS OF CELECOXIB FOR THE MANAGEMENT OF LOW BACK PAIN AT THE SOCIAL SECURITY MEXICAN INSTITUTE
Arreola-Ornelas H 1 , Rosado-Buzzo A 1 , García-Mollinedo L 1 , Dorantes-Aguilar L 2 , Muciño-Ortega E 3 , Mould-Quevedo JF 3 1 Links & Links, Mexico City, Mexico, 2 Links & Links, Mexico City, Mexico, Mexico, 3 Pfizer S.A. de C.V., México City, Mexico OBJECTIVES: The aim of this research was to estimate from an institutional perspective the cost-effectiveness of celecoxib against other usual analgesics for the treatment of adult patients with low-back pain. METHODS: A complete economic evaluation was conducted using a Markov model. Four health-states were used by the Markov model to assess the disease history within a 12-month time horizon. Treatments used in the evaluation were: Celecoxib 200 mg/day, naproxen 1 gr/day (oral) for 14 days; diclofenac 150 mg/day (intramuscular) for two days followed by diclofenac 200 mg/ day (oral) for 12 days; tramadol/acetaminophen 75 mg/day (oral) for 14 days and acetaminophen 1500 mg/day (oral) for 14 days. Effectiveness measures were: mean reduction of pain >50% vs. baseline (through visual analog scale questionnaire) and mean reduction in days of hospitalization. Hospital records were collected in several institutional Mexico City hospitals (n = 15,723). Unit costs were obtained from clinical records and official databases from patients seen in the Social Security Mexican Institute. Probabilistic sensitivity analyses were performed employing bootstrapping techniques and acceptability curves were constructed. RESULTS: Celecoxib treatment showed the highest mean pain reduction with 57% [CI95% 55-58%] followed by tramadol/acetaminophen with 46% [45-48%] and acetaminophen with 42% [40-43%]. The celecoxib-treated group also showed the lowest rate of hospitalization 0.17 [0.16-0.18] followed by tramadol/acetaminophen with 0.19 [0.19-0.20] and naproxen with 0.23 [0.23-0.24]. Celecoxib showed an ICER of US$471.71 for the mean pain reduction and US$1,088.48 for the mean reduction of hospitalized days measurement against diclofenac (case base). The latter was confirmed by Monte Carlo first-order simulations and acceptability curves. CONCLUSIONS: Celecoxib was more costeffective as a treatment for adult patients with low back-pain (higher effectiveness with low annual costs) than other usual analgesics.
PSY29 MODELING THE COST-EFFECTIVENESS OF BORTEZOMIB FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES
Wang ST 1 , Huang H 2 , Shi H 2 , Duh MS 1 , Chen K 1 , Chang E 1 , Korves C 1 , Dhawan R 3 , Cakana A 4 , van de Velde H 5 , Esseltine DL 2 , Garrison L 6
